BARRIERA MUCOSA: IL VERO AGENTE PROVOCATORE PER LE IBD

The intestinal barrier, an arbitrator turned provocateur in IBD Mehandru S, and Colombel JF Key studies published in 2020 demonstrate that an impaired intestinal barrier precedes clinical diagnosis of inflammatory bowel disease (IBD) by years. Furthermore, studies identify novel regulators of the intestinal barrier, including intestinal macrophages and diurnal variations of diet–microbiome interactions, which could…

NUOVO STRUMENTO PER VALUTARE LA DIFFERENZA CLINICA NELLE META-ANALISI !

A new tool to assess Clinical Diversity In Meta‐analyses (CDIM) of interventions M Barbateskovic et al. HIGHLIGHTS What is new? This paper describes Clinical Diversity In Meta-analyses (CDIM), the first tool scientifically developed to assess clinical diversity in meta-analyses Key findings: CDIM was developed using a rigorous methodology and consists of four domains: setting diversity;…

TROPPI TRIAL RIDONDANTI: EVIDENZA DI ALTA CERTEZZA NON RICHIEDE PIU’ STUDI ! UNO STUDIO DAL CILE

Registered trials address questions already answered with high-certainty evidence: a sample of current redundant research. Laura Vergara Merino et al. Highlights Redundant trials exist despite previous findings of the same clinical question. Existing high certainty evidence may not be considered when planning new trials. Redundant trials should be avoided because of their ethical implications. ABSTRACT…

EVIDENCE BASED MANAGEMENT DELLO SCOMPENSO ACUTO CARDIACO. UNA OTTIMA REVIEW

Review: Evidence-Based Management of Acute Heart Failure Arjun K. Gupta, et al. Abstract Acute heart failure (AHF) is a complex, heterogeneous clinical syndrome with high morbidity and mortality, incurring significant healthcare costs. Patients transition from home to the emergency department, the hospital and home again, and require decisions surrounding diagnosis, treatment and prognosis at each…